Clinical Trial Update: Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nilotinib alone or with imatinib for advanced gastrointestinal stromal tumor; the study was terminated but results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Gleevec (Imatinib)
• Tasigna (nilotinib)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: GIST, Metastatic Disease | Phase 2 | Status: TERMINATED | Results posted: 2017-03-15